Evidence map›Paper›PMID 38478332›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2024

Cancer Stem Cells: Current Challenges and Future Perspectives.

Muhammad Vaseem Shaikh, Stefan Custers, Alisha Anand, Petar Miletic, Chitra Venugopal, Sheila K Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. The role of stem cells in precision medicine: next-generation cancer treatment.Journal of the Egyptian National Cancer Institute · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Muhammad Vaseem Shaikh *Department of Surgery, McMaster University, Hamilton, ON, Canada.
Stefan Custers *Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
Alisha AnandDepartment of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
Petar MileticDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Chitra VenugopalDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Sheila K SinghDepartment of Surgery, McMaster University, Hamilton, ON, Canada. ssingh@mcmaster.ca.
McMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite major advances in health care including improved diagnostic tools, robust chemotherapeutic regimens, advent of precision, adjuvant and multimodal therapies, there is a major proportion of patients that still go on to experience tumor progression and recurrence. Cancer stem cells (CSCs) are shown to be responsible for tumor persistence and relapse. This subpopulation of cancer cells possess normal stem cell like traits of self-renewal, proliferation, and multilineage differentiation. Currently, they are isolated and enriched based on the cell surface markers that can be detected and sorted through fluorescence and magnetic-based cell sorting. In this chapter, we review the current challenges and limitations often encountered in CSC research, including the identification of universal markers, therapy resistance, and new drug development. Current and future perspectives are discussed to address these challenges including utilization of cutting-edge technologies such as next-generation sequencing to elucidate the genome, epigenome, and transcriptome on a single-cell level and genome-wide CRISPR-Cas9 screens to identify novel pathway-based targeted therapies. Further, we discuss the future of precision medicine and the need for the improvement of clinical trial designs.

Indexed as

NeoplasmsHumansNeoplastic Stem CellsTranscriptomeCancer stem cellsCell surface makersCRISPR-Cas9 systemFluorescent activated cell sortingIntratumoral heterogeneityMinimal residual disease.Single cell RNA sequencingStandard of careTumor initiating cells

Identifiers

PMID38478332
OpenAlexW4392776487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.